- Evelo Biosciences (NASDAQ:EVLO): Q3 GAAP EPS of -$0.63 misses by $0.09.
- As of September 30, 2021, cash and cash equivalents were $95.9 million, as compared to cash and cash equivalents of $68.9 million as of December 31, 2020.
- Research and Development Expenses: R&D expenses were $22.6 million for the three months ended September 30, 2021, compared to $14.9 million for the three months ended September 30, 2020.
Evelo Biosciences EPS misses by $0.09
Recommended For You
More Trending News
About EVLO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EVLO | - | - |
Evelo Biosciences, Inc. |